ReviewVirus research2009
Influenza vaccines based on virus-like particles.
Review in Virus research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 135 citations in OpenAlex.
- Immunopotentiation by Natural Extracts: Mechanisms and Applications in Influenza Vaccine Adjuvant Development.Food science & nutrition · 2026Review
- Influenza virus-like particles presentingNanomedicine (London, England) · 2025Article
- Nanoparticle-Based Antiviral Vaccines for Chickens: Recent Advances and Future Perspectives.Transboundary and emerging diseases · 2025Review
- Expression of Influenza M2e-NP Recombinant Fusion Protein inVaccines · 2022Article
- Article
- Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases.Clinical microbiology reviews · 2022Review
- Emerging threats and vaccination strategies of H9N2 viruses in poultry in Indonesia: A review.F1000Research · 2022Review
- Evaluation of Protective Efficacy of Influenza Virus Like Particles Prepared from H5N1 Virus of Clade 2.2.1.2 in Chickens.Vaccines · 2021Article
- Virus-like Particle Vaccines: A Prospective Panacea Against an Avian Influenza Panzootic.Vaccines · 2020Review
- Production of influenza virus-like particles using recombinant insect cells.Biochemical engineering journal · 2020Article
- Influence of temperature on the antigenic changes of virus-like particles.Clinical and experimental vaccine research · 2020Article
- Progress in the development of virus-like particle vaccines against respiratory viruses.Expert review of vaccines · 2020Review
- Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections.Frontiers in immunology · 2019Review
- Risk of influenza infection with low vaccine effectiveness: the role of avoidance behaviour.Epidemiology and infection · 2019Article
- Virus-Like Particles Expressing Toxoplasma gondii Rhoptry Protein 18 Induces Better Protection Than Rhoptry Protein 4 against T. gondii Infection.The Korean journal of parasitology · 2018Article
- Purification of influenza virus-like particles using sulfated cellulose membrane adsorbers.Journal of chemical technology and biotechnology (Oxford, Oxfordshire : 1986) · 2018Article
- Novel Platforms for the Development of a Universal Influenza Vaccine.Frontiers in immunology · 2018Review
- Virus like particle-based vaccines against emerging infectious disease viruses.Virologica Sinica · 2016Review
- Evaluation of protective efficacy induced by virus-like particles containing a Trichinella spiralis excretory-secretory (ES) protein in mice.Parasites & vectors · 2016Article
- Production of Japanese Encephalitis Virus-Like Particles Using Insect Cell Expression Systems.Methods in molecular biology (Clifton, N.J.) · 2016Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The simultaneous expression of structural proteins of virus can produce virus-like particles (VLPs) by a self-assembly process in a viral life cycle even in the absence of genomic material. Taking an advantage of structural and morphological similarities of VLPs to native virions, VLPs have been suggested as a promising platform for new viral vaccines. In the light of a pandemic threat, influenza VLPs have been recently developed as a new generation of non-egg based cell culture-derived vaccine candidates against influenza infection. Animals vaccinated with VLPs containing hemagglutinin (HA) or HA and neuraminidase (NA) were protected from morbidity and mortality resulting from lethal influenza infections. Influenza VLPs serve as an excellent model system of an enveloped virus for understanding the properties of VLPs in inducing protective immunity. In this review, we briefly describe the characteristics of influenza VLPs assembled with a lipid bilayer containing glycoproteins, and summarize the current progress on influenza VLPs as an alternative vaccine candidate against seasonal as well as pandemic influenza viruses. In addition, the protective immune correlates induced by vaccination with influenza VLPs are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.